In The Media…
MassDevice
October 21, 2021
In September, we proudly welcomed Evan Brasington to the Perineologic team. With broad experience in the urology space, Evan will play an important role in expanding adoption of the PrecisionPoint™ Transperineal Access System to provide patients with a safe, precise biopsy option. Check out this MassDevice article covering Evan’s appointment as chief commercial officer.
“We have the potential to transform prostate biopsy with an approach that is shown to result in better cancer detection and reduced infection rates.”
Evan Brasington
Chief Commercial Officer
Former Boston Scientific executive Evan Brasington joins Perineologic
September 29, 2021 – By DANIELLE KIRSH
Corbin Clinical Resources’s Perineologic this week announced that it appointed Evan Brasington as chief commercial officer.
Brasington will be responsible for leading the Cumberland, Maryland–based prostate biopsy innovation company’s commercial strategy including operations, marketing, sales and distribution.
“We are very pleased to welcome Evan to the Perineologic team. He brings more than 30 years of leadership experience in the medical device sector, including planning and execution of global marketing and sales strategies to grow marketplace adoption of new technological solutions,” president and founder Matthew Allaway said in a news release. “Our company is dedicated to bringing patients a better, safer and more precise option for prostate biopsy, and Evan’s deep knowledge of the urology market will be invaluable in expanding adoption of the PrecisionPoint system in the years ahead.”
Prior to joining the company, Brasington held numerous leadership positions at Boston Scientific for 24 years and most recently served as a divisional VP of global market development, acquired technologies, urology and pelvic health. He has also held numerous leadership roles at Johnson & Johnson and PepsiCo.
“I believe very strongly in the work that Dr. Allaway and his team are doing and that Perineologic is well-positioned to shift the way clinicians perform prostate cancer biopsies with the innovative and proven-effective PrecisionPoint technology,” Brasington said. “We have the potential to transform prostate biopsy with an approach that is shown to result in better cancer detection and reduced infection rates”.
(link to article on MassDevice.com)
Former Boston Scientific executive Evan Brasington joins Perineologic
Former Boston Scientific executive Evan Brasington joins Perineologic
September 29, 2021 – By DANIELLE KIRSH
Corbin Clinical Resources’s Perineologic this week announced that it appointed Evan Brasington as chief commercial officer.
Brasington will be responsible for leading the Cumberland, Maryland–based prostate biopsy innovation company’s commercial strategy including operations, marketing, sales and distribution.
“We are very pleased to welcome Evan to the Perineologic team. He brings more than 30 years of leadership experience in the medical device sector, including planning and execution of global marketing and sales strategies to grow marketplace adoption of new technological solutions,” president and founder Matthew Allaway said in a news release. “Our company is dedicated to bringing patients a better, safer and more precise option for prostate biopsy, and Evan’s deep knowledge of the urology market will be invaluable in expanding adoption of the PrecisionPoint system in the years ahead.”
Prior to joining the company, Brasington held numerous leadership positions at Boston Scientific for 24 years and most recently served as a divisional VP of global market development, acquired technologies, urology and pelvic health. He has also held numerous leadership roles at Johnson & Johnson and PepsiCo.
“I believe very strongly in the work that Dr. Allaway and his team are doing and that Perineologic is well-positioned to shift the way clinicians perform prostate cancer biopsies with the innovative and proven-effective PrecisionPoint technology,” Brasington said. “We have the potential to transform prostate biopsy with an approach that is shown to result in better cancer detection and reduced infection rates”.